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ABSTRACT
Objective: A simple, robust, precise, and selective stability-indicating liquid chromatography (LC) method (reverse-phase high-performance LC) was 
developed for the estimation of simeprevir through quality by design paradigm.
Methods: The chromatographic separation was performed on Water’s 2695(Alliance) equipped with a photodiode array detector at 300 nm. 
The method was developed on Discovery C18 column (250×4.6, 5 mm) using orthophosphoric acid and acetonitrile (55:45 % v/v) with the 
flow rate of 1 ml/min at 30°C. The degradation studies of simeprevir were carried out under the stress conditions of hydrolysis (acid, base, and 
neutral), oxidation, photolytic, and thermal as per the International Conference on Harmonization (ICH) guidelines. The peroxide hydrolysis 
shows more critical impurities which were well resolved from pure drug with the application of design of experiment and optimized the 
method.
Results: Independent variables (critical analytical attributes) selected for the method optimization were mobile phase ratio, flow rate, and temperature 
of the column based on the risk assessment. The retention time and resolution were selected as the method response. In response surface method, 
the central composite design and 23 factorial designs were employed for the optimization of the method. The polynomial equation was derived for the 
estimation of method response.
Conclusion: The method was optimized for better resolution among the drug, and impurity peaks were then validated as per the ICH parameters.
Keywords: Central composite design, Design of experiments, Method variables, Quality by design and stability-indicating assay.
INTRODUCTION
One of the most crucial steps in the development of pharmaceutical 
products is to assess the stability of the product. The stability-
indicating assay can assess the stability of the product by subjecting 
the product under stress condition. It is essential to separate, detect, 
and quantify the pharmaceutical and its degradation products without 
interference by stability-indicating assay method. The convenient 
method to achieve the goal of stability-indicating method is reverse-
phase (RP) liquid chromatography (LC), but often this method 
encounters the method failure or method transferability problem. 
This problem arises due to the lack of understanding of product and 
process. The success of a LC stability-indicating assay totally depends 
on its selectivity of the method [1]. To establish a robust, selective 
stability-indicating method, it requires deeper knowledge on the 
product and process along with the identification of risk factors. 
Hence, the quality by design (QbD) paradigm’s principles have been 
utilized to develop a successful stability-indicating method. The 
International Conference on Harmonization (ICH) Q8 (R1) guideline 
defines QbD as “a systematic approach to development that begins 
with predefined objectives and emphasizes product and process 
understanding and process control, based on sound science and 
quality risk management” [2,12,13].
Hepatitis C is a liver disease caused by the hepatitis C virus (HCV); 
the virus can cause both acute and chronic hepatitis. In recent years, 
progress in the development of direct-acting antiviral to treat chronic 
HCV infection has accelerated enormously, so the number of affected 
people count was decreased in worldwide. According to the WHO’s 
Global Hepatitis, report estimates that 71 million people in 2015 
were living with HCV, down from an earlier estimate of 130 million to 
150 million [3]. Simeprevir is the second-generation NS3/4A protease 
inhibitors which was used in the treatment of genotype 1 HCV infection 
(Fig. 1). NS3/4A protease acts on NS3 site for cleaving and generation of 
new proteins. Simeprevir is competitive, macrocyclic NS3/4A protease 
inhibitor that inhibits HCV NS3/4A protease’s cleavage of the HCV 
polyprotein by binding non- covalently and preventing viral replication 
in infected cells [4,5].
In the literature review, there was one method reported on stability-
indicating assay of simeprevir [6] and few bioanalytical methods 
were developed using LC with tandem mass spectrometry (MS) [7], 
ultra-performance liquid chromatography-MS [8], and isocratic RP 
high-performance LC (RP-HPLC) [9]. There was a spectrophotometric 
method for the estimation of Simeprevir and its oxidative degradation 
product [10] and one molecular modeling, in-silico toxicity by 
spectrofluorimetry method on simeprevir [11].
It is a clear evident from the literature, and no method has been 
developed through QbD approach. The reported stability-indicating 
method also not focused on any risk assessment and robustness of the 
method. Hence, there is a need to develop a robust, precise, simple, 
cost-effective, and selective stability-indicating RP-HPLC method on 
simeprevir in bulk drug through the QbD approach.
© 2019 The Authors. Published by Innovare Academic Sciences Pvt Ltd. This is an open access article under the CC BY license (http://creativecommons. 
org/licenses/by/4. 0/) DOI: http://dx.doi.org/10.22159/ajpcr.2019.v12i5.32027
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MATERIALS AND METHODS
Reagents and chemicals
The active pharmaceutical ingredient was purchased from MSN 
Pharmaceuticals, Hyderabad. HPLC-grade water was purchased from 
Rankem, Avantor Performance Materials India Limited. Orthophosphoric 
acid (OPA) was purchased from RFCL, Rankem Limited, India. High-purity 
water was prepared using a Millipore Milli Q Plus purification system.
Instrument
LC equipment used for the development was WATERS 2695 equipped 
with a photodiode array (PDA) detector using Empower 2 software 
(Waters Corporation, Milford, MA, USA).
Chromatographic conditions
The chromatographic separation was performed on Discovery 
C18 (250 mm×4.6, 5 µm) at 300 nm. The column temperature was 
maintained at 30°C. The mobile phase was OPA and acetonitrile (ACN) 
(55:45) with a flow rate of 1 ml/min.
Preparation of standard solutions
Buffer (0.1% OPA)
Add 1 ml of OPA solution in a 1000 ml of volumetric flask, add about 
100 ml of milli-Q water and final volume make up to 1000 ml with 
milli-Q water.
Standard preparation
Accurately weighed and transferred 25 mg of simeprevir working 
standards into a 25 ml clean dry volumetric flask, add three-fourth 
volume of diluents, sonicated for 5 min, and make up to the final volume 
with diluents.
Standard preparation for linearity
Pipette 0.25, 0.50, 0.75, 1.0, 1.25, and 1.50 ml of above standard stock 
solution into 10 ml of standard flask and make up to the mark with 
diluents. The concentration of simeprevir in the prepared solution was 
25, 50, 75, 100, 125, and 150 µg/ml.
Standard preparation for degradation
About 1 ml of stock solution of simeprevir was taken separately and treated 
with acid, base, hydrogen peroxide separately at different Concentrations. 
After degradation the solution was neutralised and diluted to obtain 
100ppm of simeprevir. Later it was injected into LC system.
Design of expert software
The design expert software 11.0.5.0 free trial version was used to plan 
the experiment’s design.
RESULTS AND DISCUSSION
Defining quality target profile
It is a prospective summary of quality characteristics of a drug product 
taking into account together with the attributes affecting method 
performance. The major quality characteristic of a drug product which 
affects the method performances includes dosage form, color, and 
impurity percentage.
Selection of chromatographic conditions
Simeprevir maximum absorbance wavelength was selected at 300 nm 
from scanning the range of 200–400 nm using 25 µg/ml of standard 
solution of the drug. The elution was carried on C8 and C18 column, 
but the peak shape obtained on Discovery C18 column with good 
system suitability parameters. The PDA detector was used to detect 
the simeprevir. The mobile phase used for the detection was OPA and 
ACN in the ratio of 55:45 at the flow rate of 1 ml/min. The column 
temperature was maintained at 30°C.
Forced degradation
Stress degradation studies of simeprevir were carried out under 
hydrolysis (acid, base, and neutral), oxidation, and photolytic. The drug 
was treated with 0.1N HCl for 6 h at 60°C to perform acid degradation, 
1 N NaOH for 3 h at 60°C for base degradation, and 20% H2O2 for 3 h 
at 60°C for peroxide degradation. The standard drug solution was 
placed in an oven at 105°C for 6 h to study dry heat degradation. Stress 
testing under neutral conditions was studied by refluxing the drug in 
water for 72 h at a temperature of 60°C. The chromatograms of forced 
degradation studies of simeprevir are shown in Fig. 2.
The simeprevir drug was stable under the stress condition of thermal, 
UV, and water. The drug was treated under acidic and basic condition, 
and its shows degradation with one degradant peak in each condition. 
However, in 20% hydrogen peroxide, the peroxide shows two degradant 
peaks which are more likely to coelute with the drug peak. Results of 
the percentage of degradations of simeprevir lies within accepted limits 
and are mentioned in Table 1.
Hence, it is evident that the peroxide condition has a significant effect on 
the stability of simeprevir drug than any other stress condition. Hence, 
the emphasis has given the peroxide stress condition to understand 
method variables on method response. So, design of experiments (DoE) 
has applied on peroxide stress condition.
Risk assessment
The critical method variables are the parameters which have impact on 
the quality target profile. “It is a systematic process for the assessment, 
control, communication, and review of risks to the quality across the 
product lifecycle.” It is done throughout the life cycle and typically 
performed. The risk factors for simeprevir method were identified based 
on the theoretical and practical knowledge and are given in Table 2.
Design of experiment
Based on the risk assessment, the critical analytical attributes were 
identified % OPA in the mobile phase, the flow rate, and column 
temperature. The method responses selected were retention time of 
the drug and resolution between the drug peak and degradation peak 
1 which likely coelutes and leads to method failure often. Preferably 
in response surface method, 23 factorial designs were selected. The 
selected method responses and its levels are given in Table 3.
The central composite design was selected and 20 chromatogram runs 
were conducted as per DoE design, and the method responses of each 
run are mentioned in Table 4.
Statistical analysis of method responses
Analysis of variance (ANOVA) for method response 1 – retention time
The ANOVA of regression parameters of the predicted response surface 
quadratic model for retention time was obtained from DoE software 
Fig. 1: Structure of simeprevir
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and is presented in Table 5. The model shows F value of 36.46 and 
low probability value which states that the model was significant for 
retention time. Values of “Prob > F” <0.0500 indicate that model terms 
were significant. In this case, A, B and A2 were significant model terms. 
Values > 0.1000 indicate that the model terms were not significant. The 
The “ Lack of Fit F-Value of 4.88 implies that there was a 5.34 % chance 
that it could occur due to noise. Adequate precision 22.230 indicates an 
adequate signal. This model can be utilized to navigate the design space.
Based on results, the response surface model constructed in this study 
for predicting retention time was considered reasonable. The final 
regression model, in terms of their coded factors was given below 
equation.
RT = +5.26+2.24A−0.29B−0.049C+0.072A×B−5.375e−0.003A×C−0.023B× 
C+0.74 A2+ 0.091B2+0.053C2
The equation in terms of actual factors can be used to make predictions 
about the response of retention time and process variables by 
polynomial equation.
Table 1: Degradation percentage of simeprevir under various 
stress conditions
Condition % Assay 
initial
% Assay after 
degradation
% Degradation
Acid 100.00 79.48 20.51
Base 100.00 70.29 29.70
Peroxide 100.00 78.82 21.17
Thermal 100.00 101.99 0.651
UV degradation 100.00 93.37 6.625







pH of mobile phase Control
Percentage of OPA in mobile phase Variable X1
Flow rate of Mobile phase Variable X2
Temperature of column Variable X3
HPLC: High-performance liquid chromatography, OPA: Orthophosphoric acid
Table 3: Design of experiments – Levels of variables









% mobile phase (OPA) % 50.00 55.00 60.00
Flow rate ml/min 0.90 1.00 1.10
Column temperature °C 28 30 32
OPA: Orthophosphoric acid
Fig. 2: Forced degradation chromatograms of simeprevir. (a) Acid degradation: In 0.1 N HCl at 60°C for 6 h, (b) Base degradation: In 1N 
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RT =  +98.83993−2.95197×MP−25.55454×FR−0.67258×TMP+0.14475 
MP×FR−5.37500E−004MP×TMP−0.11688FR−TMP+0.029732MP2+ 
9.11590FR2+0.013244 TMP2
3D and contour graph for retention time
The 3D surface response and contour plots of the quadratic model were 
given by the Design–Expert software which provides the interactive 
relationship of two factors on response by keeping constant of the third 
factor.
The contour and 3D surface response in Fig. 3 states that the highest 
retention time reached below 8 min only when maintaining the 60.00% 
of OPA in mobile phase and 1.10 ml/min flow rate by keeping constant 
of column temperature at 30°C. Below 51% of OPA at 0.9 ml/min, the 
retention time of the drug was eluted <4 min which is not recommended.
The flow rate kept constant and interaction of % OPA and column 
temperature were studied on retention time as shown in Fig. 4. It shows 
that, at low levels of % OPA and temperature, retention time reduced to 
below 4 min. At high levels of variables, the retention time achieved at 
7.6 min.
The % OPA in the mobile phase kept constant at 55 and interaction 
of flow rate on column temperature was studied. These two factors 
show the least effect on retention time of the drug. Changing these two 
factors from low to high levels which has least effect on retention time 
of Simeprevir. Hence, these two-term interactions were insignificant in 
this model.
ANOVA for method response 2 – resolution
The ANOVA of regression parameters of the predicted response surface 
quadratic model for resolution was obtained from DoE software and is 
Table 4: Central composite design for screening of method parameters










% ml/min °C Time (min) Number
6 1 60 0.9 32 9.103 3.5
13 2 55 1 26.63 5.165 3.9
3 3 50 1.1 28 3.687 4.4
1 4 50 0.9 28 4.516 2.5
14 5 55 1 33.36 4.949 4.5
19 6 55 1 30 5.105 3.9
9 7 46.59 1 30 3.594 4
11 8 55 0.83 30 5.499 4.2
18 9 55 1 30 5.447 4
8 10 60 1.1 32 8.47 1.6
10 11 63.40 1 30 10.425 2
12 12 55 1.16 30 4.831 3.9
4 13 60 1.1 28 8.636 1.6
20 14 55 1 30 5.044 3.5
2 15 60 0.9 28 9.11 3.5
7 16 50 1.1 32 3.608 5.3
15 17 55 1 30 5.042 4
17 18 55 1 30 5.559 3.5
16 19 55 1 30 5.679 4
5 20 50 0.9 32 4.465 2.6
Table 5: ANOVA for quadratic model for method response – retention time





Model 77.43 9 8.60 36.46 <0.0001 Significant
A-MP 68.26 1 68.26 289.23 <0.0001
B-FR 1.12 1 1.12 4.76 0.0541
C-TMP 0.033 1 0.033 0.14 0.7183
AB 0.042 1 0.042 0.18 0.6824
AC 2.311E-004 1 2.311E-004 9.794E-004 0.9757
BC 4.371E-003 1 4.371E-003 0.019 0.8944
A² 7.96 1 7.96 33.74 0.0002
B² 0.12 1 0.12 0.51 0.4925
C² 0.040 1 0.040 0.17 0.6876
Residual 2.36 10 0.24
Lack of 
fit





Cor Total 79.79 19
ANOVA summary
SD 0.49 PRESS 15.39 Adequate 
precision
22.230
R² 0.9704 Adjusted 
R²
0.9438 Predicted R² 0.8072
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given in Table 6. The Model F-value of 10.51 implies that the model was 
significant. There is only a 0.05% chance that a “Model F-value” this large 
could occur due to noise. Values of “Prob > F” <0.0500 indicate that model 
terms were significant. In this case, A, AB, and A2 were significant model 
terms. Values >0.1000 indicate that the model terms were not significant. 
The “Lack of Fit F-Value of 4.67 implies that there was a 5.34 % chance 
that it could occur due to noise. The “Predicted R-Squared” of 0.3739 was 
not as close to the “Adjusted R-squared” by 0.8183 as one might normally 
expect. However, the “adequate precision” ratio of 12.716 indicates an 
adequate signal, which measures the signal to noise ratio.
Based on results, the response surface model constructed in this study 
for predicting retention time was considered reasonable. The final 




The equation in terms of actual factors can be used to make predictions 





3D and contour graph for retention time
The column temperature was kept constant at 30°C, and the remaining 
two variables such as % OPA and flow rate interaction effect on 
resolution are studied from Fig. 5. At higher levels, the % OPA and 
flow rate give low resolution (˂2). % OPA ranges lies above 50.00% to 
below 57.50% at the flow rate of 1.0 ml/min or lower levels yield good 
resolution between the peaks.
The flow rate kept constant at 1 ml/min, and then the interaction of % 
OPA and column temperature on resolution was studied from Fig. 6 . It 
Table 6: ANOVA for quadratic model for method response – resolution





Model 16.54 9 1.84 10.51 0.0005 Significant
A-MP 4.64 1 4.64 26.55 0.0004
B-FR 6.392E-003 1 6.392E-003 0.037 0.8522
C-TMP 0.30 1 0.30 1.69 0.2228
AB 8.82 1 8.82 50.43 < 0.0001
AC 0.13 1 0.13 0.71 0.4177
BC 0.080 1 0.080 0.46 0.5142
A² 2.54 1 2.54 14.52 0.0034
B² 0.034 1 0.034 0.19 0.6689
C² 2.908E-004 1 2.908E-004 1.663E-003 0.9683
Residual 1.75 10 0.17




Cor Total 18.29 19 18.29
ANOVA summary
SD 0.42 PRESS 11.45 Adequate precision 12.716
R² 0.9044 Adjusted 
R²
0.8183 Predicted R² 0.3739
Fig. 3: Response surface (a) and contour plots (b) for retention time as a function of orthophosphoric acid % in mobile phase and flow 
rate, ml/min (contact temperature: 30°C)
a b
Fig. 4: Response surface (a) and contour plots (b) for retention time as a function of orthophosphoric acid % in mobile phase and 
temperature, °C (constant flow rate, 1.00 ml/min)
a b
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shows that if method operated at high levels of % OPA and temperature, 
the method response resolution achieved < 3.6. But operating the 
method at low level of OPA %(< 55%) and high level of temperature 
(>30ºC) can gives rise the resolution more than 4.
The % OPA in mobile phase kept constant at 55, and the interaction of 
flow rate and column temperature was studied which shows the least 
effect on resolution. Hence, it is considered as insignificant terms for 
this proposed model.
Design space
The design space can provide a suitable method performance such 
as retention time and resolution of the method within the space. 
The method failure has been detected by a proper understanding of 
method variable interaction by keeping constant of one variable and 
studying the two factors interaction on method performance. By careful 
observation of the contour and 3D diagram, the design space for the 
method was obtained which can produce acceptable system suitability 
parameters values as given in Table 7.
Method optimization through DoE software
The accuracy of the model was evaluated by numerical optimization 
method by the Design-Expert software. The desired goals for method 
response, retention time (3.594–10.425), and Resolution (1.6–5.3) were 
set as in rage. 30 solutions were suggested, but based on desirability 
1.0, the software selected one condition. The experiment run was 
conducted based on the optimal condition mentioned in Design-Expert. 
The chromatographic conditions suggested by Design-Expert were % 
OPA in mobile phase at 51.3%, flow rate at 0.94 ml/min, and column 
temperature at 30.13°C and predicted method responses by the model 
were retention time at 4.27 min and resolution at 3.56 as shown in Fig. 7.
The same experimental conditions were maintained and run the HPLC 
system. The optimized chromatogram of simeprevir with peroxide 
impurities was obtained as indicated in Fig. 8 and it produced satisfactory 
system suitability parameters. The method responses of simeprevir in 
chromatogram had shown almost nearer to predict values.
The verification data of predicted values by the model and observed 
values are given in Table 8.
The correlation between the predicted values and observed values was 
found to be 1 as given in Fig. 9. Hence,the model successfully can predict 
the method response within the 95% of the confidence interval of low 
and high.
The proposed optimized method was validated as per ICH parameters. 
Validation summary data are provided in Table 9.
DISCUSSION
A novel, selective, robust stability-indicating RP-HPLC method 
was developed for the estimation of simeprevir in bulk drug by 
QbD approach. Initial method was developed using OPA and ACN 
Fig. 7: Optimization and prediction of method responses by model
Fig. 5: Response surface (a) and contour plots (b) for the resolution as a function of orthophosphoric acid % in mobile phase and flow 
rate, ml/min (contact temperature: 30°C)
a b
Fig. 6: Response surface (a) and contour plots (b) for resolution as a function of orthophosphoric acid % in mobile phase and 
temperature, °C (constant flow rate of 1.00 ml/min)
a b
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(55:45% v/v) with the flow rate of 1 ml/min at 300 nm. The drug was 
subjected to various stress conditions such as hydrolysis (acid, alkali, 
and neutral), peroxide, and thermal. Under peroxide stress conditions, 
the chromatogram shows more number of critical impurity peaks which 
affect the selectivity of method. To resolve it, the design of experiment 
was applied. In response surface method, central composite design 
was used by taking three factors like % OPA, pH, and flow rate as input 
variables. The retention time and resolution were output variables. 
The statistical tools were implemented to know the significant effect 
of each factor on method responses. The polynomial equation was 
derived for retention time and resolution. Chromatographic conditions 
suggested by Design-Expert were OPA % in mobile phase at 51.3%, 
flow rate at 0.94 ml/min, and column temperature at 30.13 ºC. The 
model predicted that the retention time of simeprevir was 4.27 and 
resolution was 3.56. The method was verified by performing the 
above-mentioned chromatographic conditions. The retention time 
and resolution obtained in these conditions were 4.108 min and 3.4. 
With 95 % of confidence interval, the proposed model can predict the 
response variables. The optimized method was validated as per the ICH 
Q2 (R1) guidelines.
CONCLUSION
A quadratic model of a central composite design with a high degree 
of correlation and predicting ability was developed to predict the 
retention time of simeprevir and resolution between simeprevir and 
its degradant using OPA % in mobile phase, flow rate, and column 
temperature as method variables. Interaction among all the variables 
was investigated by employing RSM. The significant effect was shown by 
% OPA in mobile phase on both response retention time and resolution. 
The accuracy of the model was tested by running the chromatographic 
condition suggested by the model. The forecast values of retention time 
and resolution by the design were matched with the observed values. 
The method was optimized and validated as per the ICH guidelines.
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Fig. 8: Optimization chromatogram of simeprevir in peroxide degradation
Fig. 9: Correlation graph of predicted values versus observed 
values
Table 7: Method operable design region









Temperature (30°C) 50–55 0.9–1.0 Constant
Flow rate (1.0 ml/min) 50–55 Constant 28–32




Table 8: Verification of experiment at optimum conditions
Method 
response





Retention time 4.27 3.81 4.75 4.108
Resolution 3.56 3.16 3.96 3.4
CI: Confidence interval






LOD (µg/mL) 0.96 µg/ml
LOQ (µg/mL) 2.90 µg/ml
Accuracy (Average recovery %) 101.89
Precision (% RSD)
Intraday precision 0.2
Inter day precision 0.3
Robustness Robust
LOD: Limits of detection, LOQ: Limits of quantification, RSD: Relative standard 
deviation
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